Oppenheimer Maintained Perform on GoPro (GPRO) After Meeting with Management
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Citi Sees Weak Near-Term Results for GoPro (GPRO) But Says Concerns Priced In
September 17, 2015 9:04 AM EDTCiti analysts are cutting near-term estimates on GoPro (NASDAQ: GPRO) but reiterated a Buy rating and $90 price target on GoPro (NASDAQ: GPRO), saying weak Q3 and Q4 results are largely priced in and HERO4 concerns create an attractive entry point.
The analysts noted that CFO Lazar confirmed at... More
GoPro (GPRO) Gains as Two Bullish Pieces Embolden Investors
September 14, 2015 12:10 PM EDTAfter seeing tremendous pressure over the past few weeks, shares of GoPro (NASDAQ: GPRO) are up 4.4% Monday, benefiting from two items: 1. The WSJ posted a bullish-leaning Heard on the Street Column "Shredded GoPro Finally Looks Like a Deal"; 2. Northland... More
Pre-Open Stock Movers 09/14: (COLL) (AQXP) (SLH) Higher; (RPTP) (BABA) (GOLD) Lower (more...)
September 14, 2015 9:23 AM EDTCollegium Pharmaceutical, Inc. (NASDAQ: COLL) 33% HIGHER; confirmed late Friday that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted unanimously to support the approval of Xtampza ER (oxycodone extended-release capsules) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Raptor Pharma (NASDAQ: RPTP) 27.4% LOWER; announced topline... More
GoPro's (GPRO) Addressable Market Seen at ~$20B
September 14, 2015 6:47 AM EDTGoPro (Nasdaq: GPRO) shares are on watch following mixed commentary in the WSJ over the weekend.
The WSJ noted recent... More
